Frequently Asked Questions

Q: How do research-grade adenovirus vectors support accelerated IND-enabling toxicology studies?

High-quality, well-characterized research-grade adenovirus vectors provide the foundation for reproducible preclinical data. By ensuring high purity and consistent titer, these vectors minimize experimental variability, which allows for a clearer interpretation of toxicology and efficacy endpoints. This reliability is a key factor in assembling a robust data package to meet 18-24 month IND timelines.

Q: What strategies mitigate immunogenicity for adenovirus vectors in preclinical models?

Mitigating the inherent immunogenicity of adenoviral vectors is a primary consideration. Strategies include the use of novel serotypes derived from nonhuman primates to bypass pre-existing neutralizing antibodies in test systems. Surface modification techniques such as PEGylation can also be employed to shield the vector from the host immune system, potentially reducing T cell responses and enabling assessments of readministration.

Q: Can adenovirus vectors be produced under conditions suitable for early-stage GxP programs?

Yes. Research-grade vectors can be produced with rigorous quality control and documentation practices that align with the requirements for IND-enabling studies conducted under GxP conditions. This includes detailed characterization of vector identity, purity, and concentration, ensuring the material is appropriate for generating the safety and biodistribution data required by the FDA.

The utility of adenovirus (AdV) as a vector for next-generation therapeutics is well-established, particularly for applications requiring high transduction efficiency and robust transgene expression. For program leaders targeting an 18-24 month timeline to IND, the quality of the research-grade vector used in pivotal preclinical studies is a determining factor for success. Inconsistent vector quality can introduce artifacts that obscure safety signals and efficacy readouts, delaying program progression.

A forward-thinking preclinical strategy considers the immunological profile of the adenoviral vector from the outset. Standard human AdV serotypes can encounter pre-existing neutralizing antibodies (NAbs) in nonhuman primate models, complicating data interpretation. One effective approach involves utilizing a panel of vectors based on non-human primate isolates, which often exhibit low NAb prevalence in relevant test systems (PMID: 21259405). This selection process helps ensure that the observed biological effects are attributable to the therapeutic payload, not a confounding immune response to the vector itself.

Further de-risking of an AdV program can be achieved through vector engineering. Surface modification, such as PEGylation, has been shown to reduce vector immunogenicity in vivo. This technique can attenuate T cell and NAb responses, prolonging transgene expression and creating opportunities to evaluate readministration regimens in preclinical models (PMID: 12396620). Generating this type of data early provides a significant advantage when designing a clinical development plan.

Executing these advanced vector strategies requires deep operational expertise. As one client noted, “Kenton and team are always exceptional in their willingness to help and make sure they are providing the best service possible. This vector release request was followed up in a matter of a few hours and was delivered overnight and ready for use.” This level of responsiveness is built upon the long-standing experience of our scientific team, which transitioned from the Penn Vector Core to Franklin Biolabs. Our work is conducted in a >100,000 sq ft facility designed for complex preclinical and bioanalytical programs.

The scientific leadership and core operational team at Franklin Biolabs, which formally launched in 2024, have maintained a 100% successful IND rate since 2019. This track record reflects a deep understanding of the data required for successful regulatory submissions. Our expanded services in adenovirus and lentivirus production are a direct extension of this expertise, detailed further on our parent hub page for AAV Research Vector Packaging Services.